The Pravetoni Lab

...towards novel therapies to treat prescription opioid abuse



Coming soon


Baruffaldi F, Raleigh MD, King S, Roslawski M, Birnbaum A, Hassler C, Carroll FI, Runyon SP, Winston S, Pentel PR, Pravetoni M. Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation. Molecular Pharmacology, 2019, April 24. DOI: 10.1021/acs.molpharmaceut.8b01296.

Robinson C, Baehr C, Schmiel SE, Accetturo C, Mueller DL, Pravetoni M. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders. Human Vaccines & Immunotherapeutics, 2019, January 9:1-9. DOI: 10.1080/21645515.2018.1558697.

Raleigh MD, Baruffaldi F, Peterson SJ, Le Naour M, Harmon TM, Vigliaturo JR, Pentel PR, Pravetoni M. A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats. Journal of Pharmacology and Experimental Therapeutics, 2019, Feb; 368(2):282-291.

Baehr C, Pravetoni M. Vaccines to treat opioid use disorders and to reduce opioid overdoses. Neuropsychopharmacology, 2019, January; 44(1):217-218.


Baruffaldi F, Kelcher AH, Laudenbach M, Gradinati V, Limkar A, Roslawski M, Birnbaum A, Lees A, Hassler C, Runyon S, Pravetoni M. Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. Molecular Pharmacology, 2018, November 5; 15(11):4947-4962.

Laudenbach M, Baruffaldi F, Robinson C, Carter P, Seelig D, Baehr C, and Pravetoni M. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports, 2018, April 3; 8(1):5508. DOI: 10.1038/s41598-018-23777-6.

Raleigh MD, Laudenbach M, Baruffaldi F, Peterson SJ, Roslawski MJ, Birnbaum AK, Carroll FI, Runyon SP, Winston S, Pentel PR, and Pravetoni M. Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats. JPET. March 13, 2018, jpet.117.247049; DOI: Link.


Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, Navarro HA, Langston TL, Runyon SP, Winston S, Pravetoni M and Pentel PR. Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse. PLoS One. 2017 Dec 1;12(12):e0184876. doi: 10.1371/journal.pone.0184876. eCollection 2017.

Mavrikaki Maria, Pravetoni Marco, Page Sarah, Potter David, and Chartoff Elena. Oxycodone self-administration in male and female rats. Psychopharmacology. 2017, Jan 27. doi: 10.1007/s00213-017-4536-6.


Pravetoni M. Biologics to treat substance use disorders: current status and new directions. Solicited review. Human Vaccines & Immunotherapeutics. 2016; Jul 21:1-15.


Laudenbach M, Tucker AM, Runyon SP, Carroll FI, Pravetoni M. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine. 2015;33(46):6332-6339.

Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M. The frequency of naïve and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse. The Journal of Immunology. 2015;194(12):5926-5936.

Kotecki L, Hearing M, McCall NM, Marron Fernandez de Velasco E, Pravetoni M, Arora D, Victoria NC, Munoz MB, Xia Z, Slesinger PA, Weaver CD, Wickman K. GIRK channels modulate opioid-induced motor activity in a cell type- and subunit-dependent manner. The Journal of Neuroscience. 2015;35(18):7131-7142.


Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLOS One. 2014;9(7):e101807.

Pravetoni M, Vervacke JS, Distefano MD, Tucker AM, Laudenbach M, Pentel PR. Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats. PLOS One. 2014;9(5):e96547.

Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK, Pravetoni M. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. Journal of Immunology Methods. 2014;405:74-86.


Cornish KE, de Villiers SH, Pravetoni M, Pentel PR. Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions. PLOS One. 1013;8(12):e82557.

de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 2013;31(52):6185-6193.

Pravetoni M, Le Naour M, Tucker AM, Harmon TM, Hawley TM, Portoghese PS, Pentel PR. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. Journal of Medicinal Chemistry. 2013;56(3):915-923.

Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. The Journal of Pharmacology and Experimental Therapeutics. 2013;344(2):397-406.


Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine. 2012;31(1):159-164.

Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, Birnbaum AK, Portoghese PS, Pentel PR. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine. 2012;30(31):4617-4624.

LeSage MG, Shelley D, Pravetoni M, Pentel PR. Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacology, Biochemistry, and Behavior. 2012;102(1):157-162.

Pravetoni M, Le Naour M, Harmon TM, Tucker AM, Portoghese PS, Pentel PR. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. The Journal of Pharmacology and Experimental Therapeutics. 2012;341(1):225-232.

Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, Earley CA, Pentel PR. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochemical Pharmacology. 2012;83(4):543-550.


Pravetoni M, Keyler DE, Raleigh MD, Harris AC, LeSage MG, Mattson CK, Pettersson S, Pentel PR. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochemical Pharmacology. 2011;81(9):1164-1170.

2010 and Older

Arora D, Haluk DM, Kourrich S, Pravetoni M, Fernández-Alacid L, Nicolau JC, Luján R, Wickman K. Altered neurotransmission in the mesolimbic reward system of GIRK mice. Journal of Neurochemistry. 2010;114(5):1487-1497.

Anderson GR, Cao Y, Davidson S, Truong HV, Pravetoni M, Thomas MJ, Wickman K, Giesler GR Jr., Martemyanov KA. R7BP complexes with RGS9-2 and RGS7 in the striatum differentially control motor learning and locomotor responses to cocaine. Neuropsychopharmacology. 2010;35(4):1040-1050.

Perry CA, Pravetoni M, Teske JA, Aguado C, Erickson DJ, Medrano JF, Luján R, Kotz CM, Wickman K. Predisposition to late-onset obesity in GIRK4 knock-out mice. Proceedings of the National Academy of Sciences of the United States. 2008;105(23):8148-8153.

Cruz HG, Berton F, Sollini M, Blanchet C, Pravetoni M, Wickman K, Lüscher C. Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice. Journal of Neuroscience. 2008;28(15):4069-4077.

Pravetoni M, Wickman K. Behavioral characterization of mice lacking GIRK/Kir3 channel subunits. Genes, Brain and Behavior. 2008;7(5):523-531.

Anderson GR, Lujan R, Semenov A, Pravetoni M, Posokhova EN, Song JH, Uversky V, Chen CK, Wickman K, Martemyanov KA. Expression and localization of RGS9-2/G 5/R7BP complex in vivo is set by dynamic control of its constitutive degradation by cellular cysteine proteases. Journal of Neuroscience. 2007;(51):14117-14127.

Mendoza-Baumgart MI, Pravetoni M, Sparber SB. Inhibition of nitric oxide synthase enhances cocaine’s developmental toxicity: vascular and CNS Effects. Neuropsychopharmacology. 2007;32(4):940-945.

Mendoza-Baumgart MI, Pravetoni M, Sparber SB. Vasoconstriction caused by cocaine is enhanced by sodium salicylate: is inducible nitric oxide synthase mRNA related? Neuropsychopharmacology. 2004;29(7):1294-1300.

Robert C, McGraw S, Massicotte L, Pravetoni M, Gandolfi F, Sirard MA. Quantification of housekeeping transcript levels during the development of bovine preimplantation embryos. Biology of Reproduction. 2002;67(5):1465-1472.